An open label parallel randomised Phase-II comparative study to evaluate safety, tolerability and immunogenicity of two intramuscular doses of 14-valent pneumococcal polysaccharide conjugate vaccine administered 2 months apart to 12-23 month-old healthy Indian PCV-naïve toddlers
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Jan 2019
At a glance
- Drugs Pneumococcal conjugate vaccine 14-valent - Biological E Limited (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Biological E Limited
- 30 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Jan 2018 Status changed from not yet recruiting to recruiting.
- 03 Jan 2018 New trial record